GreenWay Herbal Products Secures a New Patent
GreenWay Herbal Products, LLC has recently made headlines by announcing that the United States Patent and Trademark Office granted them a significant patent related to cannabinoids. This important intellectual property, known as U.S. Patent No. 12,496,307, focuses on a 1-to-1 equimolar composition of cannabidiol (CBD) and cannabidiolic acid (CBDA).
The Significance of the Patent
Titled Cannabinoid compositions and methods of using, the patent offers robust protections for GreenWay’s unique cannabinoid formulation. The company has invested heavily in cannabinoid science over nearly ten years, striving to understand how these compounds act at the molecular level. Their research, conducted in collaboration with Middle Tennessee State University (MTSU), showed that this specific formulation performed significantly better than CBD alone, especially in suppressing cytokine storm activity in animal studies.
Expert Insights from GreenWay's CEO
Jeff Heeren, the Chief Executive Officer of GreenWay Herbal Products, stated that this milestone represents the culmination of focused research and development efforts. He expressed confidence in the pharmaceutical potential of their 1-to-1 cannabinoid formulation, highlighting its scientific advancements. Heeren remarked, “This patent confirms the scientific differentiation and pharmaceutical potential of our 1-to-1 cannabidiol and cannabidiolic acid formulation.”
Expanding International Patent Portfolio
The issuance of this patent marks an essential step in GreenWay's strategy to build a broad intellectual property portfolio on an international scale. Notably, patents in the United Kingdom have already been granted, and similar applications are currently being pursued in Canada, the European Union, Israel, and Thailand. These international efforts further solidify GreenWay’s position in the industry by protecting their innovations globally.
Potential Applications of the Cannabinoid Composition
The patent encompasses numerous claims about methods for treating inflammation and various autoimmune conditions. Among these are rheumatoid arthritis, Crohn's disease, lupus erythematosus, and multiple sclerosis, to name a few. The comprehensive list of allowed claims can be referenced under U.S. Patent No. 12,496,307.
Future Directions for GreenWay
GreenWay plans to leverage this patent to advance a regulated pharmaceutical development program, ensuring compliance with U.S. Food and Drug Administration (FDA) regulations. The company believes the patented formulation has significant potential to act as either a complement to or an alternative for existing anti-inflammatory and autoimmune therapies, while also upholding the safety factors associated with cannabinoid use when managed under medical supervision.
Heeren elaborated on their plans, stating that the company aims to utilize this patent as a foundation for various business strategies. This includes furthering their pharmaceutical development initiatives and seeking strategic licensing opportunities with pharmaceutical and biotechnology firms. GreenWay is also exploring the integration of their patented compound with innovative delivery systems and complementary therapies.
About GreenWay Herbal Products, LLC
Established in 2016, GreenWay Herbal Products, LLC is dedicated to botanical research and product development anchored in Tennessee. With a strong focus on evidence-based botanical innovations, the company has forged a fruitful partnership with Middle Tennessee State University to develop a comprehensive intellectual property portfolio surrounding cannabinoid formulations.
Frequently Asked Questions
What is the focus of the newly issued patent?
The patent focuses on a 1-to-1 composition of cannabidiol (CBD) and cannabidiolic acid (CBDA) aimed at treating inflammation and autoimmune diseases.
How does GreenWay plan to use the patent?
GreenWay intends to use this patent for pharmaceutical development and to establish strategic partnerships in the health sector.
What were the findings from the preclinical research?
Research indicated that the CBD and CBDA formulation showed significantly improved performance in suppressing cytokine storm activity compared to CBD alone.
In which countries is GreenWay seeking patent protection?
GreenWay is pursuing patent applications in Canada, the European Union, Israel, and Thailand, alongside the UK, where protection has already been granted.
When was GreenWay Herbal Products, LLC established?
The company was founded in 2016 and focuses on evidence-based research in botanical product development.
